keyword
https://read.qxmd.com/read/38536033/treatment-outcomes-in-older-patients-with-metastatic-breast-cancer-receiving-palbociclib-plus-an-aromatase-inhibitor-a-plain-language-summary
#1
REVIEW
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo
WHAT IS THIS SUMMARY ABOUT?: This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptorpositive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines - palbociclib and an aromatase inhibitor - compared with taking an aromatase inhibitor alone...
March 27, 2024: Future Oncology
https://read.qxmd.com/read/38535156/survival-analysis-of-male-patients-with-brain-metastases-at-initial-breast-cancer-diagnosis-over-the-last-decade
#2
JOURNAL ARTICLE
Jorge Avila, Julieta Leone, Carlos T Vallejo, José P Leone
Breast cancer in men represents approximately 1% of all breast cancer diagnoses. Among all patients with breast cancer, approximately 30% will develop brain metastases. Over the past decade, there have been multiple advances in the treatment of metastatic breast cancer; however, long-term outcomes of this presentation in male patients are lacking. We evaluated male patients with de novo stage IV breast cancer using the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2019. Overall survival (OS) was estimated using the Kaplan-Meier method and differences between groups were compared using log rank tests...
March 10, 2024: Medical Sciences: Open Access Journal
https://read.qxmd.com/read/38531793/characterizing-the-efficacy-and-safety-of-chemotherapy-plus-everolimus-in-her2-negative-metastatic-breast-cancer-harboring-altered-pi3k-akt-mtor
#3
JOURNAL ARTICLE
Rong Wang, Qiao-Yan Zhu, Wei-Wu Ye, Yuan Huang, Zhan-Hong Chen, Ya-Bing Zheng, Xiao Zou, Jian Wang, Dan-Lu Jiang, Xiao-Jia Wang, Zheng-Yang Xu, Wen-Ming Cao
BACKGROUND: The clinical outcomes of chemotherapy (CT) for the treatment of metastatic triple-negative (TN) and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) have proven to be disappointing. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, a tumor-promoting signaling cascade frequently mutated in breast cancer (BC), has been implicated in chemoresistance...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38529509/overcoming-brain-derived-therapeutic-resistance-in-her2-breast-cancer-brain-metastasis
#4
Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R Del Bigio, Xin Xu, Amy Wang, Raul Calvo, Abhijeet Kapoor, Juan J Marugan, Mark J Henderson, Thomas Klonisch, Sabine Hombach-Klonisch
Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with Trastuzumab +/-HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis (BCBM). The scarcity of suitable patient-derived in-vivo models for HER2+ BCBM has compromised the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis...
February 22, 2024: bioRxiv
https://read.qxmd.com/read/38528295/a-real-world-study-of-treatment-sequences-and-second-line-clinical-outcomes-in-patients-with-her2-positive-metastatic-breast-cancer-in-us-community-practice
#5
JOURNAL ARTICLE
Della Varghese, Giovanna I Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C Faherty, David Harland, Henry G Kaplan
PURPOSE: Standard-of-care for HER2-positive metastatic breast cancer (HER2 + mBC) patients consists of trastuzumab ± pertuzumab with chemotherapy in first-line (1L), and ado-trastuzumab emtansine (T-DM1) or the more recently approved trastuzumab deruxtecan (T-DXd) in second-line (2L). Contemporary data on treatment sequencing and real-world effectiveness is limited. This study aims to report 2L treatments and outcomes among HER2 + mBC patients in the United States (US)...
March 25, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38526689/the-effects-of-low-her2-expression-on-survival-in-patients-with-metastatic-breast-cancer-treated-with-cdk-4-6-inhibitors-a-multicenter-retrospective-study
#6
JOURNAL ARTICLE
Murad Guliyev, Gülin Alkan Şen, İlkay Gültürk, Nargiz Majidova, Goncagül Akdağ, Ali Ahadzade, Hande Turna, Nebi Serkan Demirci
PURPOSE: Endocrine therapy (ET) in combination with CDK 4/6 inhibitors (CDK 4/6i) is the standard treatment modality for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (mBC). There is uncertainty about the prognostic and predictive value of HER2-low status and whether HER2-low BC is an individual biologic subtype. In this study, we aimed to investigate the prognostic effect of HER2 expression status on survival in mBC patients treated with first-line ET plus CDK 4/6i...
March 25, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38519708/elderly-patients-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-treated-with-cdk4-6-inhibitors-in-a-multicentre-cohort
#7
JOURNAL ARTICLE
Helena Pla, Eudald Felip, Verónica Obadia, Sonia Pernas, Gemma Viñas, Mireia Margelí, Roser Fort-Culillas, Sonia Del Barco, Nuria Sabaté, Eduard Fort, Clara Lezcano, Beatriz Cirauqui, Vanesa Quiroga, Agostina Stradella, Miguel Gil Gil, Anna Esteve, Sabela Recalde
INTRODUCTION: Cyclin-dependent kinases 4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have become the gold standard in hormone receptor-positive (HR +) HER2-negative (HER2-) metastatic breast cancer (MBC). However, there is a significant lack of data regarding the efficacy and safety of these treatments in elderly patients. We present the results of a real-world data (RWD) cohort stratified by age at treatment initiation (≥ 70 years compared to patients < 70 years)...
March 22, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38519706/persistence-of-peripheral-cd8%C3%A2-%C3%A2-cd28-t-cells-indicates-a-favourable-outcome-and-tumour-immunity-in-first-line-her2-positive-metastatic-breast-cancer
#8
JOURNAL ARTICLE
Xiaoran Liu, Xiangming Cheng, Feng Xie, Kun Li, Yongcan Shi, Bin Shao, Xu Liang, Fengling Wan, Shidong Jia, Yue Zhang, Yiqiang Liu, Huiping Li
BACKGROUND: The contradictory role of CD8 + CD28- T cells in tumour immunity has been reported, while their biological and clinical significance in HER2-positive metastatic breast cancer (MBC) is still unknown. METHODS: HER2-positive MBC patients with no prior therapy in the metastatic setting were retrospectively recruited at two medical centres. Peripheral CD8 + CD28- T cells (pTCD8+CD28- ) were detected at baseline and following therapeutic intervals...
March 22, 2024: British Journal of Cancer
https://read.qxmd.com/read/38518088/a-comprehensive-clinical-evaluation-of-her2-tkis-in-patients-with-previously-treated-her2-positive-metastatic-breast-cancer
#9
JOURNAL ARTICLE
Wen-Jun Ji, Xuan Lu, Yu-Gang Wang, Lin-Wei Chen
Human epidermal growth factor receptor 2-tyrosine kinase inhibitors (HER2-TKIs) have been extensively utilized for treating HER2-positive metastatic breast cancer (MBC), with numerous clinical trial reports available. We aim to systematically perform a comprehensive clinical evaluation on HER2-TKIs, provide a reference for the clinical rational use of drugs, and serve for the decision-making of the national drug policy. We performed comprehensive clinical evaluation in six dimensions including safety, effectiveness, economy, suitability, accessibility, and innovation through meta-analysis, literature review, drug administration websites, and other relevant medication data to analyze HER2-TKIs in treating HER2-positive MBC...
March 19, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38517416/prolonging-the-lives-of-african-americans-with-metastatic-breast-cancer-by-adding-palbociclib-to-an-aromatase-inhibitor-in-routine-clinical-practice-a-plain-language-summary-of-a-real-world-database-study
#10
REVIEW
Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Tiah Tomlin-Harris, Adam Brufsky
WHAT ARE THE KEY TAKEAWAYS?: This study used de-identified medical information from the Flatiron Database. This database contains healthcare information on people with cancer treated by doctors in the United States but personal information is removed to maintain privacy. Medical information for people who received certain treatments in routine clinical practice or real-world setting was included in the study. This study showed that in the real-world setting, African-Americans with HR+/HER2- MBC lived longer when receiving palbociclib with an AI than with an AI alone...
March 22, 2024: Future Oncology
https://read.qxmd.com/read/38516685/clinical-analysis-of-metaplastic-breast-carcinoma-with-distant-metastases-a-multi%C3%A2-centre-experience
#11
JOURNAL ARTICLE
Mirosława Püsküllüoğlu, Katarzyna Swiderska, Aleksandra Konieczna, Joanna Streb, Aleksandra Grela-Wojewoda, Agnieszka Rudzinska, Jolanta Dobrzańska, Renata Pacholczak-Madej, Anna Mucha-Malecka, Michał Kunkiel, Jerzy W Mitus, Michał Jarząb, Marek Ziobro
Metaplastic breast cancer (BC-Mp), which includes a range of epithelial and mixed epithelial-mesenchymal tumours, are rare malignancies with an unfavourable prognosis. The limited literature on BC-Mp focuses mainly on retrospective data for radically treated patients. Notably absent are studies dedicated to the palliative treatment of BC-Mp with distant metastases. The present retrospective study investigated treatment modalities and prognosis in a multi-centre cohort of 31 female participants diagnosed with distant metastatic BC-Mp, including 7 patients with de novo metastatic disease...
May 2024: Oncology Letters
https://read.qxmd.com/read/38514306/the-impact-of-initial-tumor-response-on-survival-outcomes-of-patients-with-her2-positive-advanced-breast-cancer-treated-with-docetaxel-trastuzumab-and-pertuzumab-an-exploratory-analysis-of-the-cleopatra-trial
#12
JOURNAL ARTICLE
Veronique Debien, Elisa Agostinetto, Marco Bruzzone, Marcello Ceppi, Diogo Martins-Branco, Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Matteo Lambertini, Evandro de Azambuja
INTRODUCTION: The CLEOPATRA trial (NCT00567190) established a dual anti-HER2 blockade in combination with docetaxel as the first-line standard of care for patients with metastatic HER2-positive breast cancer. While this treatment is overall associated with significant improvement in progression-free survival (PFS) and overall survival (OS), not all patients respond equally. We hypothesized that a radiological complete response (CR) at week 9 (i.e., first disease re-evaluation) is associated with prolonged OS and PFS compared to radiological partial response (PR) or stable disease (SD)...
February 21, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38513188/pace-a-randomized-phase-ii-study-of-fulvestrant-palbociclib-and-avelumab-after-progression-on-cyclin-dependent-kinase-4-6-inhibitor-and-aromatase-inhibitor-for-hormone-receptor-positive-human-epidermal-growth-factor-receptor-negative-metastatic-breast-cancer
#13
JOURNAL ARTICLE
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PURPOSE: Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting. METHODS: The randomized multicenter phase II PACE trial enrolled patients with hormone receptor-positive/HER2- MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy...
March 21, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38511042/atypical-co-amplification-with-co-localization-of-her2-gene-in-breast-cancer-combined-ihc-fish-approach-as-per-asco-cap-2018-guidelines-for-targeted-therapy-eligibility
#14
JOURNAL ARTICLE
Ushang Kate, Anurita Pais, Neelam Kamble, Sandhya Kandoor, Kunal Sharma
Breast cancer patients with HER2 gene amplification as assessed by FISH are eligible for HER2-targeted therapy. However, in a small subset of patients, unusual FISH pattern of co-localization and co-amplification can pose challenges in interpretation of the HER2 status and hence to assess the HER2 status accurately; our aim was to report their incidence and analyze them based on latest ASCO/CAP 2018 guidelines. We present seven cases with HER2/CEP17 co-amplification and co-localization from a total 4040 cases referred during the year 2017 to 2021 at Mumbai Reference Laboratory, SRL Diagnostics...
March 2024: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/38511041/long-term-complete-response-with-single-agent-capecitabine-in-her-2-neu-positive-metastatic-breast-cancer-a-rare-case-report
#15
Mukesh Rulaniya, Manish Sahni, Sandeep Jasuja, Suresh Singh
The standard treatment approach for metastatic breast cancer with HR- and Her-2-neu + disease is trastuzumab with systemic therapy. But in patients having severe cardiac dysfunction, trastuzumab is avoided. Various combination regimens are available in that setting, but no study has shown better efficacy of capecitabine monotherapy in this setting. We hereby present a case report of using capecitabine monotherapy in first-line setting, and the patient had complete resolution of lung metastasis from the last 2 years...
March 2024: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/38504252/soluble-periostin-is-a-potential-surveillance-biomarker-for-early-and-long-term-response-to-chemotherapy-in-advanced-breast-cancer
#16
JOURNAL ARTICLE
Li Jia, Wenwei Hu, Xu Yan, Jie Shao, Yuhong Guo, Aimin Zhang, Lianzi Yu, Yunli Zhou, Yueguo Li, Li Ren, Dong Dong
BACKGROUND: Noninvasive biomarkers for the assessment of response to chemotherapy in advanced breast cancer (BCa) are essential for optimized therapeutic decision-making. We evaluated the potential of soluble Periostin (POSTN) in circulation as a novel biomarker for chemotherapy efficacy monitoring. METHODS: Two hundred and thirty-one patients with different stages of BCa were included. Of those patients, 58 patients with inoperable metastatic disease receiving HER2-targeted or non-targeted chemotherapy were enrolled to assess the performances of markers in recapitulating the chemotherapy efficacy assessed by imaging...
March 19, 2024: Cancer Cell International
https://read.qxmd.com/read/38503755/exemestane-plus-everolimus-and-palbociclib-in-metastatic-breast-cancer-clinical-response-and-genomic-transcriptomic-determinants-of-resistance-in-a-phase-i-ii-trial
#17
JOURNAL ARTICLE
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer. The primary objective of phase Ib was to evaluate safety and tolerability and determine the maximum tolerated dose/recommended phase II dose (100 mg palbociclib, 5 mg everolimus, 25 mg exemestane)...
March 19, 2024: Nature Communications
https://read.qxmd.com/read/38503142/targeted-dual-degradation-of-her2-and-egfr-obliterates-oncogenic-signaling-overcomes-therapy-resistance-and-inhibits-metastatic-lesions-in-her2-positive-breast-cancer-models
#18
JOURNAL ARTICLE
Lu Yang, Arup Bhattacharya, Darrell Peterson, Yun Li, Xiaozhuo Liu, Elisabetta Marangoni, Valentina Robila, Yuesheng Zhang
AIMS: Human epidermal growth factor receptor 2 (HER2) is an oncogenic receptor tyrosine kinase amplified in approximately 20% of breast cancer (BC). HER2-targeted therapies are the linchpin of treating HER2-positive BC. However, drug resistance is common, and the main resistance mechanism is unknown. We tested the hypothesis that drug resistance results mainly from inadequate or lack of inhibition of HER2 and its family member epidermal growth factor receptor (EGFR). METHODS: We used clinically relevant cell and tumor models to assess the impact of targeted degradation of HER2 and EGFR on trastuzumab resistance...
March 13, 2024: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/38502995/clinical-management-monitoring-and-prophylaxis-of-adverse-events-of-special-interest-associated-with-datopotamab-deruxtecan
#19
REVIEW
Rebecca S Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S M Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. Dato-DXd is being investigated across multiple solid tumor indications...
March 11, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38497887/a-rare-case-of-takotsubo-cardiomyopathy
#20
JOURNAL ARTICLE
O Fiste, C Trika, N K Syrigos, E A Kotteas
BACKGROUND: The recent advent of the cyclin-dependent kinase (CDK) 4/6 inhibitors has considerably evolved hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer treatment. Palbociclib, an orally administered pyridopyrimidine derivative, was the first CDK4/6 inhibitor to be introduced into daily clinical practice in combination with classic endocrine backbone, based on progression-free survival (PFS) benefit assessed in the pivotal PALOMA series of randomized clinical trials...
March 2024: European Review for Medical and Pharmacological Sciences
keyword
keyword
22191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.